Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling.
Eline J H van HoutumAnne Hc ValkDaniel GranadoJasper LokLune van den BogaardNaomi RemkesJesper van Eck van der SluijsPaul N SpanLenneke A M CornelissenGosse J AdemaPublished in: Clinical & translational immunology (2024)
These data imply that immunotherapy targeting Siglec receptors may be particularly interesting for TN breast cancer patients not responding to current treatment strategies with tumors displaying high immune cell infiltration.